Zepbound 5 mg/.5mL

Tirzepatide, the active ingredient in Zepbound, is a dual GIP/GLP-1 receptor agonist presented as a 5 mg/0.5 mL injection solution for subcutaneous use. It is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, as part of a reduced-calorie diet and increased physical activity.

GNH USA supplies Zepbound as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Zepbound acts on incretin pathways involved in metabolic regulation.

- Chronic weight management: Used in adults with obesity, or overweight with at least one weight-related comorbidity, to support long-term weight reduction alongside diet and exercise. - Obesity treatment: Helps manage excess body weight in patients who meet labeled body-mass-index criteria. - Weight-related comorbidity management: May be prescribed when weight reduction is needed to address conditions associated with excess weight, as directed by a clinician.

Zepbound can cause adverse effects, including gastrointestinal and other systemic reactions.

Common Side Effects: - Nausea: Frequently reported, especially during treatment initiation or dose changes. - Diarrhea: Can occur as part of gastrointestinal intolerance. - Vomiting: May occur and can contribute to dehydration. - Constipation: Reported in some patients using tirzepatide. - Abdominal pain: May include discomfort, bloating, or cramping.

Serious or Rare Side Effects: - Pancreatitis: Severe abdominal pain with or without vomiting requires urgent evaluation. - Gallbladder problems: Gallstones or cholecystitis may occur. - Hypoglycemia: Risk is higher when used with insulin or sulfonylureas. - Kidney injury from dehydration: Can occur if significant vomiting or diarrhea leads to fluid loss.

Use Zepbound only under medical supervision and according to the approved label.

- Pregnancy: Avoid use unless a prescriber determines the expected benefit outweighs potential risk. - Breastfeeding: Discuss use with a clinician before use, since safety during lactation may be a concern. - Pancreatitis history: Use caution in patients with a prior history of pancreatitis. - Thyroid tumor risk: Do not use in patients with a personal or family history of medullary thyroid carcinoma or MEN2. - Hypoglycemia risk: Extra monitoring may be needed when combined with insulin or insulin secretagogues. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Zepbound can interact with medicines that affect glucose control or drug absorption.

Major Interactions (Avoid): - Insulin: Combined use can increase the risk of hypoglycemia and may require close clinical review. - Sulfonylureas: May also raise hypoglycemia risk when used together.

Moderate Interactions (Monitor Closely): - Oral medications with narrow therapeutic windows: Delayed gastric emptying may alter absorption. - Other glucose-lowering drugs: Additional monitoring may be needed for glycemic effects. - Medications causing dehydration: Gastrointestinal loss of fluid can compound renal risk. - Alcohol: May worsen gastrointestinal intolerance in some patients.